1-(isothiocyanatomethyl)-2-(trifluoromethyl)benzene | 51929-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(isothiocyanatomethyl)-2-(trifluoromethyl)benzene
• 英文别名: 2-trifluoromethylbenzyl isothiocyanate；2-Trifluoromethylbenzylisothiocyanate
• CAS: 51929-59-0
• 化学式: C₉H₆F₃NS
• 分子量: 217.215
• InChiKey: CQHCVTWJLMEQBK-UHFFFAOYSA-N

物化性质

• 沸点：
  241.3±35.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(isothiocyanatomethyl)-2-(trifluoromethyl)benzene 在 一水合肼 作用下， 以 乙醚 为溶剂， 反应 12.0h， 以82%的产率得到1-Amino-3-[[2-(trifluoromethyl)phenyl]methyl]thiourea
  参考文献：
  名称：

  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity

  摘要：

  The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme that has been implicated as an important drug target in various therapeutic areas, including neurological disorders (Down syndrome, Alzheimer's disease), oncology, and diabetes (pancreatic beta-cell expansion). Current small molecule DYRK1A inhibitors are ATP-competitive inhibitors that bind to the kinase in an active conformation. As a result, these inhibitors are promiscuous, resulting in pharmacological side effects that limit their therapeutic applications. None are in clinical trials at this time. In order to identify a new DYRK1A inhibitor scaffold, we constructed a homology model of DYRK1A in an inactive, DFG-out conformation. Virtual screening of 2.2 million lead-like compounds from the ZINC database, followed by in vitro testing of selected 68 compounds revealed 8 hits representing 5 different chemical classes. We chose to focus on one of the hits from the computational screen, thiadiazine I which was found to inhibit DYRK1A with IC50 of 9.41 mu m (K-d = 7.3 mu M). Optimization of the hit compound 1, using structure-activity relationship (SAR) analysis and in vitro testing led to the identification of potent thiadiazine analogs with significantly improved binding as compared to the initial hit (K-d = 71-185 nM). Compound 3-5 induced human beta-cell proliferation at 5 mu M while showing selectivity for DYRK1A over DYRK1B and DYRK2 at 10 mu M. This newly developed DYRK1A inhibitor scaffold with unique kinase selectivity profiles has potential to be further optimized as novel therapeutics for diabetes. (C) 2018 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2018.08.007
• 作为产物：
  描述：

  2-(三氟甲基)苄胺 、 硫光气 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.5h， 以81%的产率得到1-(isothiocyanatomethyl)-2-(trifluoromethyl)benzene
  参考文献：
  名称：

  Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors

  摘要：

  这项发明涉及使用吡啶并噻唑三唑二氮杂环庚烷类化合物制备用于治疗涉及生长激素释放抑制因子受体之一的病理状况或疾病的药物。该发明还涉及新型吡啶并噻唑三唑二氮杂环庚烷类化合物和含有它们的治疗组合物。

  公开号：

  US07015213B1

文献信息

• Amido macrolides
  申请人：Kosan Biosciences, Inc.

  公开号：US20030199458A1

  公开（公告）日：2003-10-23

  Various macrolide compounds such as those having the following formulas are provided where the variables have the values provided herein. 1

  各种大环内酯化合物，例如具有以下化学式的化合物，其中变量具有此处提供的值。
• Heterocyclic modulators of nuclear receptors
  申请人：——

  公开号：US20030212111A1

  公开（公告）日：2003-11-13

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节法尼索醇X受体（FXR）、肝X受体（LXR）和/或孤儿核受体活性的杂环化合物。在某些实施例中，这些化合物是噻唑啉酮衍生物。
• Differentiating Antiproliferative and Chemopreventive Modes of Activity for Electron-Deficient Aryl Isothiocyanates against Human MCF-7 Cells
  作者：Ruthellen H. Anderson、Cody J. Lensing、Benjamin J. Forred、Michael W. Amolins、Cassandra L. Aegerter、Peter F. Vitiello、Jared R. Mays

  DOI：10.1002/cmdc.201800348

  日期：2018.8.20

  cancer cells, and 2) alter cellular transcriptional profiles. This study describes the preparation of a library of non‐natural aryl ITCs and the development of a bifurcated screening approach to evaluate the dose‐ and time‐dependence on antiproliferative and chemopreventive properties against human MCF‐7 breast cancer cells. Antiproliferative effects were evaluated using a commercial MTS cell viability

  食用芸苔属蔬菜通过有机异硫氰酸酯（ITC）（芥子油苷次生代谢物酶水解的产物）提供有益效果。ITC l-萝卜硫素 ( l -SFN) 是西兰花中的主要成分，具有多种抗癌作用。虽然l -SFN等 ITC 的抗癌特性已得到广泛研究，并且l -SFN 已成为多项人体临床试验的主题，但这项工作的范围在很大程度上仅限于自然界中发现的衍生物。先前的研究表明，ITC 的结构变化可能导致化合物功效显着差异：1) 抑制癌细胞生长，2) 改变细胞转录谱。本研究描述了非天然芳基 ITC 库的制备以及分叉筛选方法的开发，以评估针对人 MCF-7 乳腺癌细胞的抗增殖和化学预防特性的剂量和时间依赖性。使用商业 MTS 细胞活力测定来评估抗增殖作用。使用抗氧化反应元件（ARE）促进的荧光素酶报告基因测定评估化学预防特性。本研究的结果确定了 1) 几个关键的结构-活性关系和 2) 用于持续开发的主要 ITC。
• 2-Nitrophenylcarbamoyl-(<i>S</i>)-prolyl-(<i>S</i>)-3-(2-naphthyl)alanyl-<i>N</i>-benzyl-<i>N</i>- methylamide (SDZ NKT 343), a Potent Human NK₁ Tachykinin Receptor Antagonist with Good Oral Analgesic Activity in Chronic Pain Models
  作者：C. Walpole、S. Y. Ko、M. Brown、D. Beattie、E. Campbell、F. Dickenson、S. Ewan、G. A. Hughes、M. Lemaire、J. Lerpiniere、S. Patel、L. Urban

  DOI：10.1021/jm970499g

  日期：1998.8.1

  A lead compound which had sub-micromolar affinity for the rabbit NK1 receptor but negligible affinity for rat NK1 receptors, 3a, was discovered by directed screening. 2-Substitution in the ring of the benzylthiourea substituent in the initial lead was found to be important, and halogens (Cl, Br) in this position were found to improve affinity for the human receptor. The activity of a series of 2-halo-substituted benzylthioureas was then optimized by modification of the proline diphenylmethyl amide, guided by a simple conceptual model based on structural overlay between these early antagonists and NK1 selective peptides. In this way, aromatic amino acid amides were identified which had improved affinity with respect to the starting diphenylmethyl (DPM) amides. The first sub-nanomolar ligand for the human NK1 receptor which arose from this series, 4af, combined a 2-chlorobenzylthiourea unit with a 2-naphthylalanine amide. Contemporaneously it was discovered that the benzylthiourea unit could be simplified to a phenylthiourea providing that an appropriate 2-substituent was also incorporated. Combination of these two series gave 2-NO2 phenylthiourea analogues which led directly to the analogous urea, 5f(2-nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide, SDZ NKT 343), a highly potent ligand for the human NK1 receptor (K-i = 0.16 nM). In addition to its high in vitro potency, 5f proved to be a potent orally active analgesic in guinea pig models of chronic inflammatory and neuropathic pain. The nature of the 2-aryl substituent was found to be critical for oral activity in this series. Clinical evaluation of 5f as a novel analgesic agent is currently underway.
• Hirashima, Akinori; Yoshii, Yutaka; Eto, Morifusa, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 7, p. 1062 - 1065
  作者：Hirashima, Akinori、Yoshii, Yutaka、Eto, Morifusa

  DOI：——

  日期：——